This site is intended for healthcare professionals
Optimising anti-TNF treatment using biosimilars Learning Zone

Expert Opinion

Last updated:29th Jun 2021
Published:29th Oct 2020

Explore independently-led content from leading experts on the use of αTNF biosimilars to treat three conditions and discover:

  • The role of αTNF biosimilars in rheumatoid arthritis and the common misconceptions of biosimilars in rheumatology
  • The considerable burden of hidradenitis suppurativa and the future of biosimilars in dermatology
  • Strategies for treating inflammatory bowel disease with αTNF biosimilars

Do you know the latest insights on the use of αTNF biosimilars in rheumatoid arthritis, hidradenitis suppurativa, and inflammatory bowel disease? In these illuminating expert-led interviews, Professor Thomas Dörner, Dr Joana Cabete, and Dr Nick Kennedy explore αTNF treatment initiation, optimisation, and maintenance, as well as αTNF treatment during COVID-19.

Also find out about the future of biosimilars in dermatology and the most common misconceptions of biosimilars in rheumatology with Professor Tiago Torres and Professor Joao Goncalves.

Know the latest insights on the use of αTNF biosimilars in rheumatoid arthritis? Watch these videos on treatment initation and optimisation.

Biological disease-modifying antirheumatic drugs (DMARDs), such as anti tumour necrosis factor (αTNF), are an important component of treatment for patients with rheumatic diseases1.

In these illuminating interviews, Professor Thomas Dörner explores the role of αTNF biosimilars in rheumatoid arthritis, including the use of biomarkers, therapeutic drug monitoring (TDM) and diagnostic techniques as well as the impact of the COVID-19 pandemic. Professor Joao Goncalves then elucidates the common misconceptions of biosimilars in rheumatology.

Factors that influence the initiation of biologic treatments

Find out the factors that influence the initiation of biologic treatments, such as early diagnosis with laboratory diagnostics using rheumatoid factor and anti-citrullinated protein antibodies, early referal, and the early initation of DMARD treatment.

Access to biologic treatment options

Learn how the arrival of αTNF biosimilars has effected access to biologic treatment options and the initiation of treatment. Also learn how various countries, including South Korea, Australia and various European nations, have expanded their use of αTNF biosimilars.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Want to hear the latest on biosimilars in dermatology? Watch the videos below to learn about the unmet needs of hidradenitis suppurativa, the impact of COVID-19, and the future of biosimilars in dermatology.

These fascinating interviews with Dr Joana Cabete and Professor Tiago Torres highlight the use of αTNF biosimilars in hidradenitis suppurativa (HS), and discuss what is on the horizon for biosimilars in dermatology.

Below, you’ll find videos on treatment options, the utility of αTNF, methods for initiation, optimisation and maintenance of treatment, the impact of COVID-19, and the future of biosimilars in dermatology.

Hidradenitis suppurativa is a prevalent and devastating inflammatory skin disease characterised by painful recurrent abscesses, foul-smelling purulent drainage, sinus tract and fistula formation, and disfiguring scarring involving intertriginous body sites1.

The burden of hidradenitis suppurativa


Hidradenitis suppurativa is a considerable burden on the life of a patient. From the difficulties of treating patients to the psychological impact it can have day to day, find out how this disease greatly effects quality of life.

Unmet needs in hidradenitis suppurativa


There has been an explosion of research in the last few years in hidradenitis suppurativa. Gain a deeper understanding of the unmet needs of this previously hidden disease, including a vicious circle of inadequate treatment and the difficulties of accessing care.

Treatment options for hidradenitis suppurativa


The stage of the disease determines the choice of treatment for hidradenitis suppurativa. Explore the treatment pathway of this disease with advice for patients, use of antibiotics such as tetracyclines, clindamycin and rifampicin as well as adjuvant therapies and biological treatments.

αTNF treatment for hidradenitis suppurativa

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Watch these videos to find out the latest advice on treating inflammatory bowel disease covering the initiation, optimisation and maintenance of treatment and impact of COVID-19.

Inflammatory bowel diseases can result in debilitating physical and psychosocial symptoms for patients and affect society through loss of schooling, absenteeism, and health-care costs1.

In this thought-provoking interview, Dr Nick Kennedy describes strategies for the initiation, optimisation and maintenance of αTNF biosimilar treatment for inflammatory bowel disease touching upon topics such as biomarkers, treatment cycling and switching, and the COVID-19 pandemic.

The impact of inflammatory bowel disease


Inflammatory bowel disease is a long term condition that significantly impacts the lives of patients. Learn about the symptoms of the disease as well as extraintestinal manifestations of symptoms. Also see how treatment and surgery can have an impact on patients.

Timely initiation of biologic treatments


Getting the right treatments to the right patients at the right time is essential to timely initiation. Find out the importance of risk stratification, access to effective treatments, effective multidisciplinery work, and patient communication.

The impact of biosimilars on access to treatment options and initiation


See how the introduction of biosimilars, such as infliximab and adalimumab, have made decisions about dose optimisation more straight forward and have led to the use of therapies earlier in the treatment course.

Treatment cycling and switching

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Professor Thomas Dörner

Meet our expert Professor Thomas Dörner, a board certified Rheumatologist and Professor of Rheumatology and Hemostaseology at Charité University Hospitals, Berlin, Germany.

Professor Joao Goncalves

Meet our expert Professor Joao Goncalves, Director of the iMed-Research Institute for Medicines, and Professor of Immunology and Pharmachology at the University of Lisbon, Portugal.

Dr Joana Cabete


Meet our expert Dr Joana Cabete, a dermatology and venereology consultant at Santo António dos Capuchos Hospital - Centro Hospitalar de Lisboa Central, Lisbon, Portugal.

Professor Tiago Torres

Meet our expert Professor Tiago Torres, a Professor of Dermatology at the University of Porto, Portugal.

Dr Nick Kennedy


Meet our expert Dr Nick Kennedy, a Consultant Gastroenterologist at the Royal Devon and Exeter NHS Foundation Trust and Honorary Clinical Senior Lecturer at the University of Exeter Medical School, Exeter, UK.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Welcome: